{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:00:56Z","timestamp":1783526456262,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NeuroSci"],"abstract":"<jats:p>Background: Prior SMA mortality studies have shown excess mortality in people with SMA, but the literature lacks data on disparities in SMA-related mortality. This study examined disparities in SMA-related mortality in the United States in the post-treatment era (2018\u20132023). Methods: This was a population-based study using the CDC Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. The International Classification of Disease (ICD), 10th Revision, Clinical Modification codes, G12.0, G12.1, G12.8, and G12.9, were used to identify SMA. The data were stratified by biological sex, race\/ethnicity (Non-Hispanic\/NH White, NH Black, Hispanic, Asian) and Census regions (West, Northeast, Midwest, South). The analysis was conducted by calculating rate ratios (RR) of age-adjusted mortality rate (AAMR). Results: There were 821 (45.8% female) SMA-related deaths across the study period. Males were associated with higher AAMR than females (RR = 1.189, 95% CI: 1.035 to 1.366). The SMA-AAMR for NH White individuals was the highest compared to Hispanic individuals (RR = 1.808, 95% CI: 1.420 to 2.300), followed by NH Black and Asian individuals. The West carried the highest AAMR compared to the Northeast (RR = 1.581, 95% CI: 1.263 to 1.978), followed by the Midwest and the South. The age at death distribution showed a bimodal pattern, as follows: 5\u201314 years and 65\u201374 years. The infant age group (&lt;1 year) was associated with the highest AAMR compared to all other age groups. Conclusion: Our findings showed that SMA-related mortality was highest in infants, NH White individuals, the West, and males. These data may assist future efforts to reduce the burden of SMA.<\/jats:p>","DOI":"10.3390\/neurosci7010022","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:48:01Z","timestamp":1770115681000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disparities in Spinal Muscular Atrophy-Related Mortality in the United States, 2018\u20132023"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-0835","authenticated-orcid":false,"given":"Ali","family":"Al-Salahat","sequence":"first","affiliation":[{"name":"Neurology Department, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-1867","authenticated-orcid":false,"given":"Rohan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Neurology Department, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy\u2014Insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell\u2019Elice, A., Alessandrelli, E., Notarangelo, S., Ranaudo, M., and Palmarini, C. (2023). Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914873"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","unstructured":"GBD 2016 Motor Neuron Disease Collaborators (2018). Global, regional, and national burden of motor neuron diseases 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 17, 1083\u20131097."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2022.189","article-title":"An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy","volume":"34","author":"Li","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","article-title":"Challenges and opportunities in spinal muscular atrophy therapeutics","volume":"23","author":"Yeo","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2147\/DDDT.S214174","article-title":"Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence","volume":"16","author":"Hjartarson","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_9","first-page":"CD006281","article-title":"Drug treatment for spinal muscular atrophy type I","volume":"4","author":"Wadman","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40120-021-00307-7","article-title":"Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls","volume":"11","author":"Viscidi","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_12","first-page":"1","article-title":"Deaths: Final Data for 2020","volume":"72","author":"Kochanek","year":"2023","journal-title":"Natl. Vital Stat. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.15585\/mmwr.mm7218a3","article-title":"Provisional Mortality Data\u2014United States, 2022","volume":"72","author":"Ahmad","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_14","unstructured":"World Health Organization (2004). ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision."},{"key":"ref_15","first-page":"E41","article-title":"Gender Effects on the Clinical Phenotype in Japanese Patients with Spinal Muscular Atrophy","volume":"63","author":"Shima","year":"2017","journal-title":"Kobe J. Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lipnick, S.L., Agniel, D.M., Aggarwal, R., Makhortova, N.R., Finlayson, S.G., Brocato, A., Palmer, N., Darras, B.T., Kohane, I., and Rubin, L.L. (2019). Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213680"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jmg.2009.066969","article-title":"Differences in SMN1 allele frequencies among ethnic groups within North America","volume":"46","author":"Hendrickson","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: Clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/pd.4459","article-title":"SMA carrier testing: A meta-analysis of differences in test performance by ethnic group","volume":"34","author":"MacDonald","year":"2014","journal-title":"Prenat. Diagn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13023-022-02280-2","article-title":"A review of the genetic spectrum of hereditary spastic paraplegias, inherited neuropathies and spinal muscular atrophies in Africans","volume":"17","author":"Mahungu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Carson, V.J., Puffenberger, E.G., Bowser, L.E., Brigatti, K.W., Young, M., Korulczyk, D., Rodrigues, A.S., Loeven, K.K., and Strauss, K.A. (2018). Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202104"},{"key":"ref_24","first-page":"39","article-title":"Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs","volume":"28","author":"Ballreich","year":"2022","journal-title":"J. Manag. Care Sp\u00e9c. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes from the First 3 Years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaneurol.2019.1206","article-title":"Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps","volume":"76","author":"Baker","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Leon-Astudillo, C., Byrne, B.J., and Salloum, R.G. (2022). Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1064194"}],"container-title":["NeuroSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-4087\/7\/1\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:17:12Z","timestamp":1770117432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-4087\/7\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["neurosci7010022"],"URL":"https:\/\/doi.org\/10.3390\/neurosci7010022","relation":{},"ISSN":["2673-4087"],"issn-type":[{"value":"2673-4087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}